Back to Search
Start Over
729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
- Publication Year :
- 2023
- Publisher :
- BMJ Publishing Group, 2023.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 11
- Issue :
- Suppl 1
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.bade833e049342d5b94d87b5f5d30fab
- Document Type :
- article
- Full Text :
- https://doi.org/10.1136/jitc-2023-SITC2023.0729